(Total Views: 135)
Posted On: 11/06/2024 8:39:54 AM
Post# of 589
Although investors are likewise disappointed the FDA did not grant or accept some part of the PMA submission IMO UEEC remains optimistic. "The company will devote its resources to completing these additional surgical procedures efficiently and is confident that the results will reinforce the results of the existing study.”
"the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult." YEA YEA YEA This is bs but in six months it should be completed. Meanwhile a serious buyer or possible financial partner could emerge IMO to fund or subsidize the clinical research!!
$5-$10+
"the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult." YEA YEA YEA This is bs but in six months it should be completed. Meanwhile a serious buyer or possible financial partner could emerge IMO to fund or subsidize the clinical research!!
$5-$10+
(0)
(0)
